Pharma: Page 19
-
Courtesy of Regeneron Pharmaceuticals
Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues
Company executives had warned investors that a delay was likely due to issues at a facility run by a third-party manufacturer.
By Kristin Jensen • Aug. 21, 2024 -
Getty Images
Lilly’s tirzepatide cuts diabetes risk, study data show
Treatment with the GLP-1 drug, which Lilly sells as Mounjaro and Zepbound, lowered the risk of Type 2 diabetes progression by 94% versus placebo.
By Ned Pagliarulo • Aug. 20, 2024 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Getty Images
As Bristol Myers’ schizophrenia drug nears approval, AbbVie and others hope to provide competition
A new wave of antipsychotics could improve patient adherence. The race to corner this large projected market is already getting tight.
By Kelly Bilodeau • Aug. 19, 2024 -
Jeenah Moon via Getty Images
Pfizer, BioNTech stumble in effort to develop combination flu, COVID shot
The vaccine didn’t spur a strong enough immune response against a particular flu strain in a Phase 3 trial, leading the companies to ponder adjustments.
By Delilah Alvarado • Aug. 16, 2024 -
Getty Images
Lilly opens R&D hub; Ovid and Lexicon lay off staff
Lilly’s new center in Boston will focus on genetic medicine research and provide lab space for startups. Elsewhere, two biotechs cut jobs and two others advanced psychedelic medicines.
By BioPharma Dive staff • Aug. 13, 2024 -
Courtesy of Merck & Co.
Immune resetMerck bets $700M on an antibody drug’s potential in immune diseases
The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.
By Ben Fidler • Aug. 9, 2024 -
Getty Images
Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study
Merck stopped a Phase 3 TIGIT study for futility. Elsewhere, shares in Cabaletta Bio sank on safety worries and Vertex secured Casgevy reimbursement in England.
By BioPharma Dive staff • Aug. 8, 2024 -
Getty Images
Zepbound shortages ease, but Lilly cautions pharmacy availability may remain ‘choppy’
After months of supply strains, Lilly has begun to catch up with demand. Consumers may still need to wait for their prescriptions to be filled, however.
By Delilah Alvarado • Aug. 8, 2024 -
Scott Olson via Getty Images
Lilly boosts outlook on rising Zepbound revenue
Sales of the in-demand obesity drug crested $1 billion in the second quarter as improved Lilly production helped the company fulfill wholesaler backorders.
By Ned Pagliarulo • Aug. 8, 2024 -
Getty Images
Amgen talks obesity drug ‘differentiation’; Servier brain cancer drug approved by FDA
Executives at Amgen had few updates on their drug MariTide, but defended what they see as the once-monthly shot’s competitive profile.
By BioPharma Dive staff • Aug. 7, 2024 -
Courtesy of Novo Nordisk
Novo shares tumble on lower-than-expected obesity drug sales
Quarterly revenue from Ozempic and Wegovy missed Wall Street estimates by about 9%, concerning some analysts and causing a stock sell-off costing the Danish drugmaker tens of billions in market value.
By Kristin Jensen • Aug. 7, 2024 -
Getty Images
Zepbound, Mounjaro back in supply as Lilly resolves shortage
All doses of the in-demand GLP-1 medicines are now available in the U.S., Lilly said ahead of reporting second quarter earnings later this week.
By Ned Pagliarulo • Aug. 5, 2024 -
Courtesy of BMS
Bristol Myers sends TIGIT drug back to Agenus
The decision makes Bristol the latest pharma to pull back on research into a type of cancer immunotherapy that’s drawn significant investment in recent years.
By Ben Fidler • Aug. 5, 2024 -
Adobe Stock / MP Studio
Sponsored by MMITWhy pharma should invest in evidence-based physician education
For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. With the advent of precision medicine, however, ongoing disease state education has become increasingly critical...
By Dr. Shrinal Patel and Carolyn Zele • Aug. 5, 2024 -
Getty Images
Vir retreats from infectious disease; Vertex shelves AATD drugs
The one-time drug developer is pivoting to cancer research. Elsewhere, Neurocrine reported a strong quarter and venBio raised half a billion dollars for biotech investing.
By BioPharma Dive staff • Aug. 2, 2024 -
Getty Images
Obesity drugsLilly obesity drug shows heart benefit in late-stage trial
The drug led to a 38% reduction in the risk of death or complications from a type of heart failure, a finding that compared favorably to available treatments.
By Ben Fidler • Aug. 1, 2024 -
Maddie Meyer via Getty Images
Moderna shares fall amid lower sales outlook for RSV, COVID shots
The biotech cited competitive pressure and “very low” expected sales in Europe for its latest guidance cut, which sent shares down by nearly 20%.
By Delilah Alvarado • Aug. 1, 2024 -
Courtesy of GSK
GSK cuts vaccine forecasts, while predicting faster overall growth
Several factors are slowing U.S. sales of Shingrix, the shingles vaccine that's become one of the British pharma's top sellers.
By Ned Pagliarulo • July 31, 2024 -
Getty Images
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
Quarterly sales of Merck’s immunotherapy crested $7 billion for the first time. Elsewhere, Fibrogen is laying off staff and Intellia has a green light to start a new gene editing trial in the U.K.
By BioPharma Dive staff • July 31, 2024 -
Courtesy of Merck & Co.
Merck shares slide as Gardasil sales drop in China
The unexpected disclosure in Merck’s second quarter earnings prompted an investor sell-off that some analysts said might be overblown.
By Kristin Jensen • July 31, 2024 -
Getty Images
Pfizer quits Duchenne gene therapy, lays off staff following study setback
The company is letting go of 150 staffers alongside a decision to officially terminate the high-profile program, which was acquired in 2016.
By Ben Fidler • July 30, 2024 -
Courtesy of GSK
GSK leans on Flagship for help finding new drugs, vaccines
The deal resembles recent Flagship alliances with Pfizer and Novo Nordisk, allowing the British pharma to comb through the company creator’s portfolio to unearth up to 10 therapies.
By Gwendolyn Wu • July 29, 2024 -
Courtesy of Boehringer Ingelheim
Boehringer adds to cancer drug pipeline with deal for startup Nerio
The pharma company will pay up to $1.3 billion to acquire San Diego-based Nerio and its research into novel immune checkpoint inhibitors.
By Ned Pagliarulo • July 29, 2024 -
Drew Angerer via Getty Images
Bristol Myers’ beat completes strong week of pharma earnings
All five large pharmaceutical companies that reported earnings last week raised either their profit or revenue guidance for the year.
By Ned Pagliarulo • July 26, 2024 -
Getty Images
Two biotechs cut staff; AbbVie weathers biosimilar threat
Glycomimetics and Cue Biopharma both revealed layoffs. Elsewhere, AbbVie’s earnings impressed Wall Street and an FDA panel recommended changing testing requirements for some lung cancer drugs.
By BioPharma Dive staff • July 26, 2024
Previous
